NASDAQ:VRNA - VERONA PHARMA P/S News Headlines

Sign in or create an account to add this stock to your watchlist.
$6.80 +0.32 (+4.94 %)
(As of 01/17/2019 02:06 AM ET)
Previous Close$6.48
Today's Range$6.45 - $7.35
52-Week Range$5.65 - $25.55
Volume60,700 shs
Average Volume21,930 shs
Market Capitalization$91.50 million
P/E Ratio-2.82
Dividend YieldN/A
Beta-0.37

Headlines

VERONA PHARMA P/S (NASDAQ VRNA) News Headlines

Source:
DateHeadline
Verona Pharma Enters Oversold TerritoryVerona Pharma Enters Oversold Territory
finance.yahoo.com - January 16 at 9:39 AM
VERONA PHARMA P/S (VRNA) Receives "Buy" Rating from WedbushVERONA PHARMA P/S (VRNA) Receives "Buy" Rating from Wedbush
www.americanbankingnews.com - January 14 at 11:40 PM
Verona Pharmas nebulized ensifentrine shows mixed results in pharmacology studyVerona Pharma's nebulized ensifentrine shows mixed results in pharmacology study
seekingalpha.com - January 14 at 9:15 AM
Verona Pharma Sees Hammer Chart Pattern: Time to Buy?Verona Pharma Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - January 11 at 10:08 AM
VERONA PHARMA P/S (VRNA) Receives Average Recommendation of "Buy" from AnalystsVERONA PHARMA P/S (VRNA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 11 at 8:21 AM
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
finance.yahoo.com - January 9 at 9:52 AM
Verona Pharma PLC American Depositary Share (VRNA)Verona Pharma PLC American Depositary Share (VRNA)
www.zacks.com - January 4 at 4:47 PM
Wedbush Analysts Give VERONA PHARMA P/S (VRNA) a $56.00 Price TargetWedbush Analysts Give VERONA PHARMA P/S (VRNA) a $56.00 Price Target
www.americanbankingnews.com - December 30 at 11:30 PM
-$0.50 EPS Expected for VERONA PHARMA P/S (VRNA) This Quarter-$0.50 EPS Expected for VERONA PHARMA P/S (VRNA) This Quarter
www.americanbankingnews.com - December 28 at 1:24 AM
Verona Pharma PLC ADRVerona Pharma PLC ADR
www.barrons.com - December 18 at 4:34 PM
Verona Pharma plc (VRNA) Commences Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDVerona Pharma plc (VRNA) Commences Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
www.streetinsider.com - December 17 at 9:42 AM
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
finance.yahoo.com - December 17 at 9:42 AM
Verona Pharma plcs (VRNA) CEO Jan-Anders Karlsson on Q3 2018 Results - Earnings Call TranscriptVerona Pharma plc's (VRNA) CEO Jan-Anders Karlsson on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 9:37 AM
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
finance.yahoo.com - November 6 at 9:35 AM
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-onVerona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on
www.nasdaq.com - October 31 at 9:44 AM
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentVerona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
finance.yahoo.com - October 31 at 9:44 AM
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis PreData from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Pre
www.nasdaq.com - October 26 at 9:48 AM
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis ConferenceData from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference
finance.yahoo.com - October 26 at 9:48 AM
Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018
finance.yahoo.com - September 27 at 9:33 AM
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International CongressVerona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress
finance.yahoo.com - September 12 at 9:19 AM
Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory JournalVerona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal
finance.yahoo.com - September 6 at 9:59 AM
Verona Pharma plc : PDMR Dealing & Issue of SharesVerona Pharma plc : PDMR Dealing & Issue of Shares
finance.yahoo.com - August 10 at 9:43 AM
Verona Pharma plcs (VRNA) CEO Jan-Anders Karlsson on Q2 2018 Results - Earnings Call TranscriptVerona Pharma plc's (VRNA) CEO Jan-Anders Karlsson on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 4:11 PM
Verona Pharma plc to Host Earnings CallVerona Pharma plc to Host Earnings Call
www.baystreet.ca - August 7 at 9:56 AM
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
finance.yahoo.com - August 7 at 9:56 AM
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance TreatmentVerona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
finance.yahoo.com - August 1 at 11:24 AM
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development UpdateVerona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update
finance.yahoo.com - July 26 at 9:45 AM
Verona Pharma plc : Notice of ResultsVerona Pharma plc : Notice of Results
finance.yahoo.com - July 26 at 9:45 AM
Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare ConferenceVerona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - July 24 at 10:01 AM
In New Jersey and 7 Other States, Democrats Fill Ranks of ChallengersIn New Jersey and 7 Other States, Democrats Fill Ranks of Challengers
www.nytimes.com - June 6 at 9:46 AM
Verona Pharmas Shelf Registration Statement declared effective by SECVerona Pharma's Shelf Registration Statement declared effective by SEC
finance.yahoo.com - June 4 at 9:36 AM
Verona Pharma plc : Block Listing UpdateVerona Pharma plc : Block Listing Update
finance.yahoo.com - May 31 at 9:56 AM
Verona Pharma to Present at Upcoming Investor ConferencesVerona Pharma to Present at Upcoming Investor Conferences
finance.yahoo.com - May 30 at 9:44 AM
Verona Pharma PLC (VRNA) Highlights Clinical Data on RPL554 as First-in-Class Treatment for COPDVerona Pharma PLC (VRNA) Highlights Clinical Data on RPL554 as First-in-Class Treatment for COPD
www.streetinsider.com - May 22 at 9:27 AM
Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International ConferenceVerona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference
finance.yahoo.com - May 9 at 9:43 AM
Verona Pharma plc : MiscellaneousVerona Pharma plc : Miscellaneous
finance.yahoo.com - May 9 at 9:43 AM
Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
finance.yahoo.com - May 8 at 9:36 AM
Verona Pharma to Present at Bio€quity Europe 2018Verona Pharma to Present at Bio€quity Europe 2018
finance.yahoo.com - May 4 at 9:35 AM
Verona Pharma plc : Result of AGMVerona Pharma plc : Result of AGM
finance.yahoo.com - May 3 at 9:33 AM
Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018Verona Pharma to Announce Operational Update and Financial Results for First Quarter Ended March 31, 2018
finance.yahoo.com - May 2 at 9:36 AM
Verona Pharma Announces Departure of Chief Medical OfficerVerona Pharma Announces Departure of Chief Medical Officer
finance.yahoo.com - April 11 at 10:23 AM
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and AmgenThe Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
finance.yahoo.com - March 29 at 10:07 AM
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPDVerona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
finance.yahoo.com - March 26 at 10:11 AM
Verona Pharma to Present at Upcoming Healthcare Investor ConferencesVerona Pharma to Present at Upcoming Healthcare Investor Conferences
finance.yahoo.com - March 15 at 9:37 AM
Grant of Options and RSUs and PDMR DealingsGrant of Options and RSUs and PDMR Dealings
finance.yahoo.com - March 9 at 10:20 AM
Verona Pharma plc : Grant of Options and RSUs and PDMR DealingsVerona Pharma plc : Grant of Options and RSUs and PDMR Dealings
finance.yahoo.com - March 9 at 10:20 AM
Verona Pharma plc : 1st Quarter ResultsVerona Pharma plc : 1st Quarter Results
finance.yahoo.com - March 8 at 10:06 AM
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis PatientsVerona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients
finance.yahoo.com - March 2 at 9:33 AM
Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017
finance.yahoo.com - February 27 at 9:42 AM
Verona Pharma plc : PDMR DealingVerona Pharma plc : PDMR Dealing
finance.yahoo.com - November 30 at 9:09 AM
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel